RT Journal Article
SR Electronic
T1 Combination of hotspot mutations with methylation and fragmentomic profiles to enhance Multi-Cancer Early Detection
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2024.08.18.24312164
DO 10.1101/2024.08.18.24312164
A1 Nguyen, Thi Hue Hanh
A1 Vu, Hoang Giang
A1 Nguyen, Thi Tu
A1 Nguyen, Anh Tuan
A1 Tran, Vu Uyen
A1 Vu, Thi Luyen
A1 Nguyen, Thi Huong Giang
A1 Nguyen, Duy Nhat
A1 Tran, Trung Hieu
A1 Nguyen, Van Thien Chi
A1 Nguyen, Thanh Dat
A1 Nguyen, Trong Hieu
A1 Vo, Dac Ho
A1 Van, Thi Tuong Vi
A1 Do, Thi Thanh
A1 Le, Minh Phong
A1 Huynh, Le Anh Khoa
A1 Nguyen, Duy Sinh
A1 Tang, Hung Sang
A1 Nguyen, Hoai-Nghia
A1 Phan, Minh-Duy
A1 Giang, Hoa
A1 Tu, Lan N
A1 Tran, Le Son
YR 2024
UL http://medrxiv.org/content/early/2024/08/19/2024.08.18.24312164.abstract
AB Background Multi-cancer early detection (MCED) through a single blood test significantly advances cancer diagnosis. However, most MCED tests rely on a single type of biomarkers, leading to limited sensitivity, particularly for early-stage cancers. We previously developed SPOT-MAS, a multimodal ctDNA-based assay analyzing methylation and fragmentomic profiles to detect five common cancers. Despite its potential, SPOT-MAS exhibited moderate sensitivities for early-stage cancers. This study investigated whether integrating hotspot mutations into SPOT-MAS could enhance its detection rates.Method A targeted amplicon sequencing approach was developed to profile 700 hotspot mutations in cell-free DNA and integrated into the SPOT-MAS assay, creating a single-blood draw workflow. This workflow, namely SPOT-MAS Plus was retrospectively validated in a cohort of 255 non-metastatic cancer patients (breast, colorectal, gastric, liver, and lung) and 304 healthy individuals.Results Hotspot mutations were detected in 131 of 255 (51.4%) cancer patients, with the highest rates in liver cancer (96.5%), followed by colorectal (59.3%) and lung cancer (53.7%). Lower detection rates were found for cancers with low tumor mutational burden, such as breast (31.3%) and gastric (41.9%) cancers. In contrast, SPOT-MAS demonstrated higher sensitivities for these cancers (51.6% for breast and 62.9% for gastric). The combination of hotspot mutations with SPOT-MAS predictions improved early-stage cancer detection, achieving an overall sensitivity of 78.5% at a specificity of 97.7%. Enhanced sensitivities were observed for colorectal (81.36%) and lung cancer (82.9%).Conclusion The integration of genetic and epigenetic alterations into a multimodal assay significantly enhances the early detection of various cancers. Further validation in larger cohorts is necessary to support broader clinical applications.Competing Interest StatementThe authors, including LST, HG, MDP, HNN, and DSN, hold equity in Gene Solutions. HG, MDP, and LST are inventors on the patent application (USPTO 17930705). We confirm that this does not alter our adherence to journal policies on sharing data and materials.Funding StatementThis work was supported by Gene Solutions (K-Discovery).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study was approved by the Ethics Committee of the Medic Medical Center, University of Medicine and Pharmacy and Medical Genetics Institute, Ho Chi Minh City, Vietnam.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesThe data that support the findings of this study are available on request from the corresponding author. The data are not publicly available due to privacy or ethical restrictions.MCEDMulti-cancer early detectionctDNAcirculating tumor DNATNBCtriple-negative breast cancerNSCLCnon-small cell lung cancerSPOT-MASScreening for the Presence Of Tumor by Methylation And SizeCHIPclonal hematopoiesis of indeterminate potentialCOSMICCatalogue of Somatic Mutations in Cancer databaseWBCsWhite blood cellsLODlimit of detectiongDNAgenomic DNAMAFmutant allele fractionTMBtumor mutational burden